Androgen Receptor Protein Levels Are Significantly Reduced in Serous Ovarian Carcinomas Compared with Benign or Borderline Disease but Are Not altered by Cancer Stage or Metastatic Progression

Hormones and Cancer

Volumn 4, Issue 3, 2013, Pages 154-164

  Butler, Miriam S ^a   Ricciardelli, Carmela ^b   Tilley, Wayne D ^a   Hickey, Theresa E ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CHAPERONE; SMALL GLUTAMINE RICH TETRATRICOPEPTIDE REPEAT CONTAINING PROTEIN ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN OVARIAN TUMOR; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELLULAR DISTRIBUTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; OVARY CARCINOMA; OVARY METASTASIS; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEROUS BORDERLINE TUMOR; SEROUS OVARIAN CARCINOMA; SIGNAL TRANSDUCTION; TISSUE SECTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84877077023     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0135-0     Document Type: Article

References (37)

1. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P (2000) Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 86(1): 40-46.
2. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC (1998) The biology of ovarian cancer. Semin Oncol 25(3): 281-304.
3. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70(2): 209-262.
4. Buchanan G, Ricciardelli C, Harris JM, Prescott J, Zoe Chiao-Li Y, Jia L, Butler LM et al (2007) Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein {alpha}. Cancer Res 67(20): 10087-10096.
5. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351(24): 2519-2529.
6. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17(2): 231-237.
7. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A et al (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124(3): 607-617. doi: 10. 1007/s10549-010-0761-y.
8. Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH (1993) An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 24(1): 90-95.
9. Cottreau CM, Ness RB, Modugno F, Allen GO, Goodman MT (2003) Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res 9(14): 5142-5144.
10. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO (2006) Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 62(4): 226-228.
11. Evangelou A, Jindal SK, Brown TJ, Letarte M (2000) Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 60(4): 929-935.
12. Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E (2000) Ovarian cancer in female-to-male transsexuals: report of two cases. Gynecol Oncol 76(3): 413-415.
13. Hickey TE, Robinson JL, Carroll JS, Tilley WD (2012) Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 26(8): 1252-1267. doi: 10. 1210/me. 2012-1107me. 2012-1107.
14. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66(2): 250-254. doi: 10. 1006/gyno. 1997. 4764.
15. Kuhnel R, Delemarre JF, Rao BR, Stolk JG (1987) Correlation of multiple steroid receptors with histological type and grade in human ovarian cancer. Int J Gynecol Pathol 6(3): 248-256.
16. Kurman RJ, McConnell TG (2010) Precursors of endometrial and ovarian carcinoma. Virchows Arch 456(1): 1-12. doi: 10. 1007/s00428-009-0824-9.
17. Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42(7): 918-931. doi: 10. 1016/j. humpath. 2011. 03. 003.
18. Lau KM, Mok SC, Ho SM (1999) Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96(10): 5722-5727.
19. Lee P, Rosen DG, Zhu C, Silva EG, Liu J (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96(3): 671-677. doi: 10. 1016/j. ygyno. 2004. 11. 010.
20. Leong CT, Ong CK, Tay SK, Huynh H (2007) Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro. Oncogene 26(6): 870-880. doi: 10. 1038/sj. onc. 1209836.
21. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B et al (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130(2): 477-487. doi: 10. 1007/s10549-011-1715-8.
22. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B et al (1995) The nuclear receptor superfamily: the second decade. Cell 83(6): 835-839.
23. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K (2010) Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 3: 14. doi: 10. 1186/1757-2215-3-14.
24. Papadatos-Pastos D, Dedes KJ, de Bono JS, Kaye SB (2011) Revisiting the role of antiandrogen strategies in ovarian cancer. Oncologist 16(10): 1413-1421. doi: 10. 1634/theoncologist. 2011-0164theoncologist. 2011-0164.
25. Prescott J, Coetzee GA (2006) Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 231(1): 12-19.
26. Ricciardelli C, Oehler MK (2009) Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 62(3): 270-275. doi: 10. 1016/j. maturitas. 2009. 01. 001.
27. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4 Pt 1): 554-559.
28. Scully RE (1995) Pathology of ovarian cancer precursors. J Cell Biochem Suppl 23: 208-218.
29. Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ (2009) Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 101(3): 498-503. doi: 10. 1038/sj. bjc. 6605153.
30. Silva EG et al (1997) The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 10(9): 879-883.
31. Slotman BJ, Kuhnel R, Rao BR, Dijkhuizen GH, de Graaff J, Stolk JG (1989) Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 33(1): 76-81. doi: 0090-8258(89)90607-0.
32. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM (1994) Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 54(15): 4096-4102.
33. van Doorn HC, Burger CW, van der Valk P, Bonfrer HM (2000) Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol 53(3): 201-205.
34. Vang R, Shih Ie M, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5): 267-282. doi: 10. 1097/PAP. 0b013e3181b4fffa00125480-200909000-00001.
35. Wang Y, Yang J, Gao Y, Dong LJ, Liu S, Yao Z (2007) Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 6(6): 864-871.
36. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128(7): 1570-1584. doi: 10. 1002/ijc. 25494.
37. Wiegratz I, Jung-Hoffmann C, Kuhl H (1995) Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 51(6): 341-346.